Results 81 to 90 of about 1,795 (145)

Treatment of Haemophilia A Without Inhibitors: Real-World Treatment Patterns and Clinical Outcomes in the US. [PDF]

Haemophilia
Wheeler AP, Amos LE, Gupta S, Bozzi S, Miles G, Hawaldar K, Wilson A, Hanson G, Cibelli E, Wilson A, Umarje S, Tardy AL, Dumont J, Neill G, Arnaud A.   +14 more
europepmc   +1 more source

Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A. [PDF]

Ther Adv Hematol
Dutta A, Dutta TS, Borboruah L, Duseja Y, Borah J, Gogoi P.   +5 more
europepmc   +1 more source

Non-factor Therapies in Hemophilia: Mechanisms, Clinical Evidence, Patient Management, and Future Perspectives. [PDF]

Adv Ther
Nakajima Y, Nogami K.
europepmc   +1 more source

Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis. [PDF]

Blood Adv
Locke M, Albiez J, Receveur N, Marbach S, Frey N, Girotra M, Wyssenbach M, Bektic L, David T.   +8 more
europepmc   +1 more source

Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database. [PDF]

J Manag Care Spec Pharm
Lee JS, Schuldt R, Xia Z, Lee L, Biondo JML, Shapiro AD.   +5 more
europepmc   +1 more source

Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis. [PDF]

Haemophilia
Bao H, Bührer C, Lin Z, Zhou L, Xia Y, Jin X, Xuan J.   +6 more
europepmc   +1 more source

Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab. [PDF]

TH Open
Nogami K, Amano K, Sawada A, Nagao A, Nagae C, Nojima M, Suzuki N, Kawano M, Shimura T, Sugao Y, Fujii T.   +10 more
europepmc   +1 more source

When and How to Start Prophylaxis in Children with Hemophilia. [PDF]

Transfus Med Hemother
Olivieri M, Königs C.
europepmc   +1 more source

Evolving landscape of haemophilia care in India: Balancing innovation, access, and sustainability. [PDF]

Indian J Med Res
Yanamandra U, Sidharthan N, John JM.
europepmc   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors. [PDF]

Haemophilia
Shima M, Fukutake K, Matsumoto M, Sugimura Y, Sugita C, Ji L, Kawano M, Matsushita T.   +7 more
europepmc   +1 more source